Meanwhile, the tumor-infiltrating CD103+ cDC1s and CD11b+ cDC2s already expressed relatively higher levels of PD-L1 in B16F10 tumor-bearing mice, which was not further enhanced by SUP3 treatment (Fig. 6C). This evidence concerns the gene ITGAM and neoplasm.